We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Value of Prostate-Specific Antigen Kinetics in Patients with Low-Risk Prostate Cancer under Active Surveillance.
- Authors
Fernández-Anguita, Pedro Jesús; Ventosa-Puig, Marta; Díaz de Mera-Sánchez Migallón, Inmaculada; Legido-Gómez, Oscar; Carrión-López, Pedro; Martínez-Ruiz, Jesus; Salinas-Sánchez, Antonio Santiago; Giménez-Bachs, José Miguel
- Abstract
Introduction: This study analyzes the value of PSA kinetics, PSA speed (vPSA), and PSA doubling time (PSAdt), in patients with low-risk prostate cancer who are in an active surveillance (AS) program. Methods: An observational, retrospective, and longitudinal study of a sample of 86 patients included in AS program between January 2014 and October 2021 was conducted. A review of their medical records was performed, and PSA kinetics were calculated, analyzing the causes of discontinuation of the AS program and its relationship with PSA kinetics. Results: The mean age was 63.39 years, and the median follow-up was 62.55 months. The mean PSA at diagnosis was 8.27 ng/mL. A median of PSAdt of 62.55 months and 1.3 ng/mL/year for vPSA was obtained. 35 patients left the program, with a higher percentage of patients leaving with a PSAdt less than 36 months (73.7 vs. 31.1%) and a vPSA greater than 2 ng/mL/year (68.2 vs. 31.3%). The probability of permanence and the time of permanence in AS were statistically significantly higher for those patients with favorable kinetic parameters. Conclusion: PSA kinetics is a parameter to take into account when making decisions to keep patients in an AS program.
- Subjects
PROSTATE cancer patients; PROSTATE-specific antigen; WATCHFUL waiting; PROSTATE cancer; PATIENT decision making
- Publication
Urologia Internationalis, 2023, Vol 107, Issue 7, p706
- ISSN
0042-1138
- Publication type
Article
- DOI
10.1159/000530963